906 results on '"Rockstroh, Jürgen K"'
Search Results
2. Antiviral treatment of COVID-19: which role can clinical parameters play in therapy evaluation?
3. People living with HIV, HCV and HIV/HCV coinfection in intensive care in a German tertiary referral center 2014–2019
4. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
5. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy
6. Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis
7. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
8. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection
9. Implementation of EACS vaccination recommendations among people living with HIV
10. Recommendations for defining preventable HIV-related mortality for public health monitoring in the era of Getting to Zero: an expert consensus
11. Impact of Hepatitis C cure on risk of mortality and morbidity in people with HIV after ART initiation
12. Reinfection incidence and risk among people treated for recent hepatitis C virus infection
13. Impact of hepatitis C cure on risk of mortality and morbidity in people with HIV after antiretroviral therapy initiation
14. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression
15. Longitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures †.
16. Still trouble with bleeding: Risk factors for HCV transmission in men who have sex with men and behavioural trajectories from 2019 to 2021
17. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)
18. SARS-CoV-2 seroconversions and chains of infection in healthcare professionals in a German maximum care provider (The CoSHeP study)
19. Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy.
20. HIV Care in Ukrainian Migrants in Two European Countries: All the Same?
21. Recently acquired HCV infection in men who have sex with men in Germany in the direct‐acting antivirals era and during the COVID‐19 pandemic.
22. Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?
23. SARS-CoV-2 PrEP complicates antibody testing after vaccination: a call for awareness
24. Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus–Infected Men Who Have Sex With Men in Berlin : A Modeling Analysis
25. Inclusive healthcare in light of the new MASLD guidelines: Should people living with HIV be screened for liver fibrosis?
26. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial
27. Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy
28. Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy
29. Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain.
30. The hepatitis C cascade of care in HIV/HCV-coinfected individuals in Europe– regional and intra-regional differences
31. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection
32. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial
33. Stage‐adapted treatment of HIV‐associated Hodgkin lymphoma: Long‐term results of a prospective, multicenter study.
34. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
35. Intestinale Erkrankungen bei HIV-Infektion
36. Impact of directly acting-antivirals and behavior change due to the COVID 19 pandemic on HCV micro-elimination in MSM in Germany
37. Early combination therapy of COVID-19 in high-risk patients
38. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1 : The EXPEDITION-2 Study
39. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
40. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
41. Ledipasvir–sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial
42. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe
43. Long‐term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir‐containing antiretroviral therapy.
44. Is Stage Conversion the Initiating Event for Reactivation of Toxoplasma gondii in Brain Tissue of Aids Patients?
45. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials
46. Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?
47. Renal safety of tenofovir alafenamide vs tenofovir disoproxil fumarate: A pooled analysis of 26 clinical trials
48. Prognostic value of non‐invasive scores based on liver stiffness measurement, spleen diameter and platelets in HIV‐infected patients
49. Kapitel 28 - Intestinale Erkrankungen bei HIV-Infektion
50. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV–Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.